February 4, 2025
TOPLINE: ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with glucocorticoid-dependent polymyalgia rheumatica […]